Analyst Price Targets — CV
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| November 4, 2025 9:17 am | — | Roth Capital | $7.00 | $4.78 | TheFly | CapsoVision resumed with a Buy at Roth Capital |
| July 28, 2025 8:32 am | Jason Wittes | Roth Capital | $6.00 | $4.00 | TheFly | CapsoVision initiated with a Buy at Roth Capital |
| May 30, 2024 11:17 am | James Quigley | Raymond James | $156.00 | $0.00 | Benzinga | Weight Loss Drug Market To Rocket To $130B By 2030 With Eli Lilly, Novo Nordisk In Lead: Goldman Sachs |
Latest News for CV
CapsoVision (NASDAQ: CV - Get Free Report) and Profusa (NASDAQ: PFSA - Get Free Report) are both small-cap manufacturing companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk and valuation. Insider and Institutional Ownership 9.8% of Profusa shares are
CNBC's Brian Sullivan reports on President Trump's commentary about Venezuela's oil industry during his meeting with oil executives at the White House.
Shares of CapsoVision, Inc. (NASDAQ: CV - Get Free Report) gapped down prior to trading on Friday. The stock had previously closed at $12.39, but opened at $10.85. CapsoVision shares last traded at $11.05, with a volume of 7,782 shares trading hands. Analysts Set New Price Targets Several equities research analysts have recently weighed in
CV seeks FDA clearance to add AI-based reading to CapsoCam Plus to boost diagnostic accuracy and streamline reviews.
U.S. stock futures mixed on Tuesday, potential stocks to watch: TEN Holdings up 17%, Fonar up 24%, CapsoVision down 11%.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CV.
U.S. House Trading
No House trades found for CV.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.